Global Mycoplasma Testing Market Is Expected To Witness A Healthy Growth Rate Of 11% By 2027

Increased research, government funding, biotechnology, pharmaceutical sectors, cell culture contamination concerns, advanced technologies, and increased respiratory tract infections is driving mycoplasma testing market.
BRUSSELS - July 26, 2023 - PRLog -- Mycoplasmas  are the smallest free-living microbes known to man, and they commonly contaminate mammalian cell cultures. To ensure the safety and integrity of vaccines and other biological cell-derived products, cell substrates and unprocessed bulk materials must be free of adventitious organisms such as mycoplasma.

Concerns about Mycoplasma contamination in cell culture are increasing. Putting market demand to the test

Mycoplasmas routinely contaminate bioprocessing and cell culture fluids. It is commonly known that beginning cell cultures have a 1% contamination rate, but continuing cell cultures have a 15% to 35% contamination rate due to mycoplasma. Mycoplasma contamination can occur as a result of inefficient culture procedures or faulty laboratory equipment. Reusing pipet tips is an example of poor culture technique that might disseminate mycoplasma-infected media into otherwise sterile media.

Key Strategies Employed by Companies and laboratories in Mycoplasma Testing market

Continuous advancements in mycoplasma detection have enabled market participants to create new, quick, and simple-to-use diagnostics. Such innovations tend to provide manufacturers a competitive advantage, therefore key companies are always focusing on investments for new product development and increasing their geographic reach to reinforce their positions in the rapidly growing Mycoplasma Testing market. Some of the recent developments are listed below-
  • In February 2023, SwiftDx announced the launch of its mycoplasma detection kit. The SwiftDx Mycoplasma Detection Kit is a new lateral flow test to detect mycoplasma contamination offering a quicker and more convenient solution
  • In April 2022, AlphaBiolabs launched sexually-transmitted infection (STI) testing for the detection of chlamydia, gonorrhoea, mycoplasma genitalium, mycoplasma hominis, trichomoniasis, ureaplasma parvum (UTI), and ureaplasma urealyticum (UTI)
  • In December 2021, Asahi Kasei Medical Co., Ltd. completely acquired Bionique Testing Laboratories LLC.
Despite challenges such as lengthy turnaround time, quality control concerns, long analytical and lead time, among others, the global mycoplasma testing market has high potential to grow at a significant rate and is expected to gain even more momentum in the coming years due to a strong emphasis on innovation, greater acceptance in biopharmaceutical manufacturers around the world, and market players' development of rapid mycoplasma testing.

Competitive Landscape Analysis: Mycoplasma Testing Market

Global mycoplasma testing market is marked by the presence of well-established market players such as Thermo Fisher Scientific, Inc. (US); Charles River Laboratories International, Inc. (US); Merck KGaA (Germany); Lonza Group (Switzerland); PromoCell GmbH (Germany); American Type Culture Collection (US); and others.

Explore Detailed Insights on Mycoplasma Testing Market Report @

Ruta Halde
Source: » Follow
Posted By:*** Email Verified
Tags:Mycoplasma Testing Market
Location:Brussels - Brussels - Belgium
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Medi-tech Insights News
Most Viewed
Daily News

Like PRLog?
Click to Share